|
|
|
Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia |
H. Yolli1, M.E. Demir2, *( ), R. Yildizhan3 |
1Private Levent Hospital, Department of Obstetric and Gynecology, Istanbul, Turkey 2Yeni Yuzyil University Faculty of Medicine, Department of Nephrology, Istanbul, Turkey 3Florence Nightingale Hospital, Department of Obstetric and Gynecology, Istanbul, Turkey |
|
|
Abstract Objectives: Lipocalin-2 (LCN-2) is an immune modulator. It is highly associated with inflammation, ischemia, neoplastic invasion, and transformation. Preeclampsia (PE) is a pregnancy-related disease resulting from the incomplete invasion of trophoblasts. Endothelial cytokines and inflammation have crucial roles in the pathogenesis of PE. We aimed to investigate serum LCN-2 levels in pregnant women with either no PE, mild PE or severe PE. Furthermore, we determined how LCN-2 levels relate to findings of Doppler ultrasound of the arteries in these patients. Material and Methods: Pregnant women with severe PE (n = 51), mild PE (n = 27), or no PE (n = 42) were involved in the study. Serum LCN-2 levels and Doppler ultrasonography (USG) evaluation were performed at the time of diagnosis of PE or in the cases of uncomplicated pregnancy, just prior to delivery. Women with non-complicated pregnancies were followed up for an additional 8 weeks after delivery. Intrauterine growth restriction (IUGR) was evaluated according to Alexander curve references. Results: Serum LCN-2 levels were significantly higher in pregnant women with PE. Higher LCN-2 levels were found in association with abnormal uterine blood flow and IUGR. Mean gestational age was lower in preeclamptic pregnancies and associated with high serum levels of LCN-2. Conclusion: PE is one of the most prevalent causes of pregnancy-associated complications. Early diagnosis and management of the disease are crucial. The level of serum LCN-2 may provide additional prognostic value along with other clinical and laboratory features of the disease.
|
Submitted: 28 August 2019
Accepted: 04 November 2019
Published: 15 August 2020
|
*Corresponding Author(s):
M.E. Demir
E-mail: demirmehmetemin@hotmail.com
|
[1] |
Gathiram P., Moodley J.: “Pre-eclampsia: its pathogenesis and pathophysiology”. Cardiovasc J Afr, 2016, 27(2), 71-78.
doi: 10.5830/CVJA-2016-009
pmid: 27213853
|
[2] |
Duckitt K., Harrington D.: “Risk factors for pre-eclampsia at antenatal booking, systemic review of controlled studies”. BMJ, 2005, 330(7491), 565.
doi: 10.1136/bmj.38380.674340.E0
pmid: 15743856
|
[3] |
Bartsch E., Medcalf K.E., Park A.L., Ray J.G.: “Clinical risk factors for pre-eclampsia determined in early pregnancy, systemic review and meta-analysis of large cohort studies”. BMJ, 2016, 353, i1753.
doi: 10.1136/bmj.i1753
pmid: 27094586
|
[4] |
Wu P., Haththotuwa R., Kwok C.S., Babu A., Kotronias R.A., Rushton C., et al.: “Preeclampsia and Future Cardiovascular Health, A Systematic Review and Meta-Analysis”. Circ Cardiovasc Qual Outcomes, 2017, 10(2), e003497.
doi: 10.1161/CIRCOUTCOMES.116.003497
pmid: 28228456
|
[5] |
Flo T.H., Smith K.D., Sato S., Rodriguez D.J., Holmes M.A., Strong R.K., Akira S., Aderem A.: “Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron”. Nature, 2004, 16,432(7019), 917-21.
|
[6] |
Devireddy L.R., Hart D.O., Goetz D.H., Green M.R.: “A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in nterobactin production”. Cell, 2010, 6, 1006-17.
|
[7] |
Mori K., Lee H.T., Rapaport D.: “Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury”. J Clin Invest, 2005, 115(3), 610-21.
doi: 10.1172/JCI23056
pmid: 15711640
|
[8] |
Chakraborty S., Kaur S., Guha S., Batra S.K.: “The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer”. Biochim Biophys Acta, 2012, 1826(1), 129-69.
doi: 10.1016/j.bbcan.2012.03.008
pmid: 22513004
|
[9] |
Cemgil Arikan D., Ozkaya M., Adali E.: “Plasma lipocalin-2 levels in pregnant women with pre-eclampsia, and their relation with severity of disease”. J Matern Fetal Neonatal Med, 2011, 24(2), 291-6.
doi: 10.3109/14767058.2010.487138
pmid: 20504246
|
[10] |
Boeldt D.S., Bird I.M.: “Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia”. J Endocrinol, 2017, 232(1), R27-R44.
doi: 10.1530/JOE-16-0340
pmid: 27729465
|
[11] |
Cnossen J.S., Morris R.K.: “Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction, a systematic review and bivariable meta-analysis”. CMAJ, 2008, 178(6), 701-11.
doi: 10.1503/cmaj.070430
pmid: 18332385
|
[12] |
Llurba E., Carreras E., Gratacós E., Juan M., Astor J., Vives A., Hermosilla E., Calero I., Millán P., García-Valdecasas B., Cabero L.: “Maternal history and uterine artery Doppler in the assessment of risk for development of early- and late-onset preeclampsia and intrauterine growth restriction”. Obstet Gynecol Int, 2009, 2009, 275613.
doi: 10.1155/2009/275613
pmid: 19936122
|
[13] |
Espinoza J., Kusanovic J.P., Bahado-Singh R., Gervasi M.T., Romero R., Lee W., et al.: “Should bilateral uterine artery notching be used in the risk assessment for preeclampsia., small-for-gestational-age., and gestational hypertension?”. J Ultrasound Med, 2010, 29(7), 1103-15.
doi: 10.7863/jum.2010.29.7.1103
pmid: 20587434
|
[14] |
American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy.: “Hypertension in pregnancy”. Report of the American College of Obstetricians and Gynecologists’. Obstet Gynecol, 2013, 122(5), 1122.
doi: 10.1097/01.AOG.0000437382.03963.88
pmid: 24150027
|
[15] |
Alexander G.R., Himes J.H., Kaufman R.B.: “A United States national reference for fetal growth”. Obstet Gynecol, 1996, 87(2), 163-8.
doi: 10.1016/0029-7844(95)00386-X
pmid: 8559516
|
[16] |
Vyakaranam S., Bhongir A.V., Patlolla D., Chintapally R.: “Study of serum uric acid and creatinine in hypertensive disorders of pregnancy”. Int J Med Sci Public Health, 2015, 4(10), 1424-1428.
doi: 10.5455/ijmsph.2015.15042015294
pmid: 27175365
|
[17] |
Fisher S.J.: “Why is placentation abnormal in preeclampsia”. Am J Gynecol, 2015, 213(4 Suppl), S115-22.
doi: 10.1016/j.ajog.2015.08.042
|
[18] |
Brosens I., Pijnenborg R., Vercruysse L., Romero R.: “The “ Great Obstetrical Syndromes” are associated with disorders of deep placentation”. Am J Obstet Gynecol, 2011, 204(3), 193.
doi: 10.1016/j.ajog.2010.08.009
|
[19] |
Parry S., McElrath T.F., Pucci D.: “Clinical risk factors for preeclampsia in the 21st century”. Obstet Gynecol, 2014, 124(4), 763-70.
doi: 10.1097/AOG.0000000000000451
|
[20] |
Skjaervan R., Vatten L.J., Wilcox A.J.: “Recurrence of pre-eclampsia across generations, exploring fetal and maternal genetic components in a population based cohort”. BMJ, 2005, 331(7521), 877.
doi: 10.1136/bmj.38555.462685.8F
pmid: 16169871
|
[21] |
Roberts J.M., Edep M.E., Goldfien A.: “Sera from preeclamptic women specifically activate human umblical vein endothelial cells in vitro, morphological and biochemical evidence”. Am J Reprod Immunol, 1992, 27(3-4), 101.
doi: 10.1111/j.1600-0897.1992.tb00735.x
pmid: 1418401
|
[22] |
Maynnard S.E., Min J.Y., Merchan J.: “Excess placental soluble fms-like thyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia”. J Clin Invest, 2003, 111(5), 649.
doi: 10.1172/JCI17189
pmid: 12618519
|
[23] |
Cowland J.B., Borregaard N.: “Molecular characteriztion and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans”. Genomics, 1997, 45(1), 17-23.
doi: 10.1006/geno.1997.4896
pmid: 9339356
|
[24] |
Harmon A.C., Cornelius D.C., Amaral L.M.: “The role of inflammation in the pathology of preeclampsia”. Clin Sci (Lond), 2016, 130(6), 409-19.
doi: 10.1042/CS20150702
|
[25] |
Karampas G., Eleftheriades M., Panoulis K.: “Maternal serum levels of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and theircomplex MMP-9/NGAL in pregnancies with preeclampsia and those with a small for gestational age neonate, a longitudinal study”. Prenat Diagn, 2014, 34(8), 726-33.
doi: 10.1002/pd.4337
pmid: 24550181
|
[26] |
D'Anna R., Baviera G., Giordano D., Todarello G., Corrado F., Buemi M.: “Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia”. Acta Obstet Gynecol Scand, 2008, 87(12), 1370-1373.
doi: 10.1080/00016340802464463
pmid: 18951213
|
[27] |
Cesur S., Yucel A., Noyan V.: “Plasma lipocalin-2 levels in pregnancy”. Acta Obstet Gnecol Scand, 2012, 91(1), 112-6.
|
[28] |
Martin A.M., Bindra R., Curcio P.: “Screenining for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation”. Ultrasound Obstet Gynecol, 2001, 18, 583-6.
doi: 10.1046/j.0960-7692.2001.00594.x
pmid: 11844193
|
[29] |
Youssef A., Righetti F., Morano D.: “Uterine artery Doppler and biochemical markers (PAPP-A., PIGF., sFlt-1., P-selectin., NGAL) at 11+0 to 13+6 weeks in the prediction of late (>34 weeks) pre-eclampsia”. Prenat Diagn, 2011, 31(12), 1141-6.
doi: 10.1002/pd.2848
pmid: 22034048
|
No Suggested Reading articles found! |
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|